Dr. Reddys Laboratories Ltd.

Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from United States Food & Drug Administration (USFDA) for its API facility in Middleburgh, New York. The USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI) and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3). Earlier on May 12, 2025, USFDA had conducted GMP inspection at company’s API Middleburgh facility in New York.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.